Testosterone Cypionate vs AndroGel: Long-Term Durability of Response

How Each Formulation Sustains Testosterone Over Time

Testosterone cypionate is an oil-based ester injected intramuscularly or subcutaneously every 7 to 14 days. After injection, the ester hydrolyzes slowly, releasing free testosterone over several days. AndroGel 1.62% is applied to the skin daily; testosterone diffuses through the stratum corneum into the circulation, reaching steady-state serum levels within about 24 hours of the first dose and maintaining them day-to-day with consistent application.

Both routes have been used for years without pharmacological tachyphylaxis. The receptor machinery does not desensitize to testosterone itself. Durability failures, when they occur, trace back to formulation-specific issues: injection site fibrosis, inconsistent dosing intervals with cypionate, or variable skin absorption and missed daily applications with the gel.

Pharmacokinetic Profile of Testosterone Cypionate

After a 200 mg IM injection, serum testosterone typically peaks at 800 to 1,100 ng/dL within 48 to 72 hours, then falls to trough levels of roughly 300 to 400 ng/dL immediately before the next injection at day 14 [1]. This peak-trough swing of 400 to 700 ng/dL is the defining pharmacokinetic feature of cypionate therapy.

Many men on 14-day cycles report energy and libido fluctuations that mirror this curve. Splitting the same total dose into weekly injections (100 mg every 7 days instead of 200 mg every 14 days) narrows the swing considerably and is endorsed by most TRT-experienced clinicians as a practical way to smooth symptom variability without changing the drug.

Pharmacokinetic Profile of AndroGel 1.62%

AndroGel 1.62% produces serum testosterone levels in the normal male range (300 to 1,000 ng/dL) in approximately 87% of men titrated to their optimal dose in the key Phase 3 trial [2]. Day-to-day variation is real: a single missed application or a shower within two hours of application can drop daily exposure by 25 to 30%.

Steady-state is reached within the first 24 hours and is maintained indefinitely as long as the patient applies the gel each morning. Unlike injections, there is no peak-trough cycle. The tradeoff is that each day represents an independent adherence decision.

Long-Term Efficacy Data: What the Trials Show

The T-Trials (NEJM 2016)

The Testosterone Trials (T-Trials) enrolled 788 men aged 65 or older with low testosterone (average 234 ng/dL at baseline) and randomized them to testosterone gel (titrated to target 500 to 1,000 ng/dL) or placebo gel for 12 months [3]. The gel arm achieved a mean serum testosterone of 454 ng/dL at month 12, compared with 228 ng/dL in the placebo arm. Sexual function, walking distance, and bone density all showed statistically significant improvements in the testosterone group.

The T-Trials used gel specifically because daily gel allows fine-dose titration without the peak-trough confounds that would complicate outcome measurement in an elderly population. The 12-month durability of serum testosterone in the treated arm was stable from month 3 onward, demonstrating that gel therapy, when adherence is controlled in a trial setting, sustains target levels reliably [3].

Injection-Based Long-Term Data

A 36-month prospective registry study published in the Journal of Clinical Endocrinology and Metabolism (N=261) found that men maintained on testosterone cypionate (mean dose 119 mg/week as split weekly injections) retained mean trough testosterone levels of 452 ng/dL at 36 months with no statistically significant decline from 6-month levels [4]. Hematocrit remained below 54% in 94% of participants when dosing was adjusted per protocol.

Injectable testosterone ester therapy has been used continuously for over 60 years without evidence of receptor downregulation. The Endocrine Society 2018 Clinical Practice Guideline states: "We recommend testosterone therapy for men with classic hypogonadism to induce and maintain secondary sex characteristics and to improve their quality of life" and lists both injectable esters and transdermal gels as acceptable first-line formulations [5].

Head-to-Head Durability Comparison

No large randomized trial has directly compared cypionate injections and AndroGel over more than 24 months with durability of serum testosterone as the primary endpoint. What exists is parallel-cohort data and registry evidence suggesting:

• Cypionate users show lower rates of treatment discontinuation at 24 months (roughly 12% vs. 28% for gel in a 2019 real-world U.S. Pharmacy claims analysis of 4,200 men) [6].
• AndroGel users who discontinue most commonly cite gel messiness, transfer concerns, or inconsistent absorption rather than therapeutic failure.
• Cypionate users who discontinue most commonly cite injection discomfort or scheduling inconvenience.

Neither formulation loses biological efficacy with time. The durability gap is a compliance gap, not a pharmacological one.

Adherence and Real-World Durability

Why Adherence Differs Between the Two Routes

Injections require a visit to a clinic or self-injection at home every 7 to 14 days. That is 26 to 52 decision points per year. Daily gel requires 365 applications per year. The arithmetic of adherence favors injections in men who are comfortable with needles.

A retrospective analysis of 1,600 men with hypogonadism in a U.S. Managed-care database found that 12-month medication possession ratio (MPR) was 0.71 for injectable testosterone versus 0.58 for testosterone gel products [7]. An MPR below 0.80 is generally considered suboptimal adherence. Both formulations underperformed that threshold in real-world use, but injections performed better.

Transfer Risk and Household Constraints

Androgen transfer from AndroGel to partners or children is a documented FDA-labeled concern. The FDA added a black-box warning to all transdermal testosterone products in 2009 after case reports of virilization in children with incidental skin contact [8]. Cypionate injections carry no transfer risk post-administration.

For men with young children at home, this single factor can override other considerations and push the clinical recommendation toward injectable therapy regardless of other preferences.

Injection Site Rotation and Long-Term Tissue Health

Repeated injection into the same site over years causes local fibrosis and may reduce absorption. A simple 4-site rotation protocol (left/right gluteus, left/right vastus lateralis) or subcutaneous abdominal rotation minimizes this. Subcutaneous testosterone cypionate at doses of 50 to 100 mg weekly has shown bioavailability equivalent to IM administration and is preferred by many patients for home self-injection because 27- to 29-gauge insulin-length needles can be used [4].

Serum Testosterone Stability: A Side-by-Side View

| Parameter | Testosterone Cypionate (weekly) | AndroGel 1.62% (daily) | |---|---|---| | Peak serum T | 700 to 900 ng/dL | 400 to 600 ng/dL | | Trough serum T | 350 to 500 ng/dL | 350 to 550 ng/dL | | Day-to-day variability | Low (between injections) | Moderate (application-dependent) | | Time to steady state | 3 to 4 weeks | 24 to 48 hours | | Monitoring draw timing | Pre-injection trough | Any morning, consistent time | | Hematocrit risk | Modestly higher (peak-driven) | Modestly lower |

The table above reflects weekly cypionate dosing specifically. Men on every-14-day cycles will see higher peaks and lower troughs, widening the variability column considerably compared with daily gel.

Switching From Testosterone Cypionate to AndroGel (or Vice Versa)

When Switching Makes Clinical Sense

Switching from injections to gel is reasonable when a patient develops injection site complications (persistent nodules, infection), has a coagulation disorder that makes IM injections risky, or consistently misses doses because of needle phobia. Switching from gel to injections is appropriate when transfer risk is identified, absorption is unreliable (BMI <18 or very thick stratum corneum in certain skin conditions), or daily adherence has been poor despite counseling.

The Endocrine Society guideline does not rank one formulation above the other as a first-line option and notes that "the clinician and patient should consider the pharmacokinetics, convenience, and side effects of each formulation" [5].

How to Execute the Switch: Cypionate to AndroGel

1. Administer the last cypionate dose on schedule.
2. Begin AndroGel 1.62% at 40.5 mg daily (two pump actuations) starting 7 days after the final injection if using a 14-day cycle, or 3 to 4 days after if using a 7-day cycle. This timing avoids a double-exposure window.
3. Check serum testosterone at 2 weeks and again at 6 weeks. Titrate gel dose in 20.25 mg increments until a mid-normal range level (400 to 700 ng/dL) is reached.
4. Draw monitoring labs (total testosterone, free testosterone, hematocrit, PSA) at 3 months post-switch, then every 6 to 12 months per the Endocrine Society 2018 guideline [5].

How to Execute the Switch: AndroGel to Cypionate

1. Discontinue gel on day 1.
2. Administer the first cypionate injection (typically 100 mg) on day 1 or day 2 of gel discontinuation. Gel's half-life after stopping is approximately 2 to 4 days, so there is no meaningful stacking effect.
3. Check trough testosterone (pre-injection) at week 4. Adjust dose and interval to target trough above 350 ng/dL.
4. Confirm hematocrit at 3 months. Injectable testosterone produces higher erythropoietic stimulation than transdermal routes at equivalent average serum levels [9].

Side Effect Profile and Long-Term Safety

Erythrocytosis Risk

Hematocrit elevation above 54% (the threshold at which most guidelines recommend dose reduction or phlebotomy) occurs more often with injectable testosterone than with gel, primarily because of the supraphysiologic peaks after injection. A 2021 systematic review of 35 trials (N=5,460) found erythrocytosis rates of 11% with injectable testosterone esters versus 5.8% with transdermal formulations [9]. Annual hematocrit monitoring is required regardless of route.

Cardiovascular Considerations

The TRAVERSE trial (N=5,204, mean follow-up 33 months) evaluated testosterone replacement in men with hypogonadism and elevated cardiovascular risk and found that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE), with a hazard ratio of 0.96 (95% CI 0.78 to 1.17) [10]. TRAVERSE used a transdermal patch, but the cardiovascular findings are generally extrapolated to other TRT formulations because serum testosterone levels were matched to the same physiologic range.

Men with polycythemia, untreated sleep apnea, or recent myocardial infarction should have a detailed risk-benefit discussion before starting any testosterone formulation.

Skin and Injection Site Reactions

AndroGel causes mild application-site reactions (erythema, dryness) in roughly 5% of users. Severe contact dermatitis is uncommon but does occur. Testosterone cypionate causes injection site pain in most patients initially; this typically improves with technique refinement and needle gauge optimization. Persistent sterile abscesses or nodules at injection sites warrant a formulation change.

Monitoring Protocol for Long-Term TRT

The Endocrine Society 2018 guideline recommends evaluating serum testosterone 3 to 6 months after starting therapy and then annually [5]. For cypionate, the draw should occur immediately before the next injection (trough). For AndroGel, the draw should occur 2 to 8 hours after application on a day with confirmed application.

Additional monitoring every 6 to 12 months includes:

• Hematocrit (adjust or hold therapy if above 54%)
• PSA (baseline, 3 to 6 months, then annually in men over 40)
• Symptom reassessment using a validated scale such as the Aging Males' Symptoms (AMS) scale
• Blood pressure
• Testicular size if fertility is a concern

Neither formulation requires liver function testing. Both are non-17-alpha-alkylated and do not carry the hepatotoxicity risk of oral androgens.

Cost, Availability, and Practical Considerations

Testosterone cypionate is available as a generic and costs approximately $30 to $60 per month at most U.S. Pharmacies for a standard weekly-injection regimen. AndroGel 1.62% branded product costs $400 to $600 per month without insurance; generic testosterone gel 1.62% has been available since 2020 and typically runs $80 to $150 per month.

Cypionate requires needles, syringes, and alcohol swabs, adding a modest supply cost. AndroGel requires no supplies but must be kept out of reach of children and pets, stored at room temperature, and applied to clean, dry skin before dressing.

For men paying out-of-pocket, the cost differential is substantial and may independently drive the durability equation: a patient who cannot consistently afford AndroGel will have worse long-term outcomes than one on affordable cypionate taken consistently.

Choosing the Right Formulation for Long-Term Success

The clinical decision framework comes down to five variables: injection comfort, household transfer risk, absorption reliability, adherence pattern, and cost. No universal ranking applies. A 45-year-old with no children at home, moderate needle tolerance, and irregular daily schedules may sustain better outcomes on cypionate. A 55-year-old with a disciplined morning routine, no needle comfort, and good insurance may do equally well on AndroGel long-term.

What the data consistently show is that when adherence is matched, serum testosterone levels and clinical outcomes are comparable between the two routes. The T-Trials demonstrated 12-month efficacy of gel in elderly men [3]. Registry data demonstrate 36-month durability of cypionate in working-age men [4]. Neither formulation wins on pharmacological grounds alone.

The practical edge for most patients in real-world settings goes to cypionate: fewer administration decisions per year, lower cost, no transfer risk, and better real-world medication possession ratios at 12 months [7].